CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
Home/Biomarker

BCR::ABL1 fusion (Ph+)

Gene: BCR::ABL1 · Type: fusion

Indications: Chronic myeloid leukemia, Acute lymphoblastic leukemia

SensitivityResistanceCIViC Context

Linked CIViC Profile: BCR-ABL

Evidence Level Distribution

Level A: 5Level B: 31Level C: 152Level D: 146
LevelTypeDirectionSignificanceDiseaseDrugsRating
APredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaImatinib5
APredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaImatinib5
APredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaImatinib5
BPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinib5
BPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaPonatinib5
ADiagnosticSupportsPositiveChronic Myeloid Leukemia4
DPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib4
BPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib4
DPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib4
APredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaDasatinib,Nilotinib4
BPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaPonatinib4
CPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib4
DPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib4
DPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib4
DPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinib4
CPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib4
CPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinib4
CPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaAxitinib4
BPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinib4
CPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinib4